View a support message for the foundation from The Wiggles
 

Scientific Advisory Board

Dr. Eric Bouffet

Head of the Neuro-oncology Section in the Division of Haematology/Oncology at The Hospital for Sick Children, Toronto

Dr. Bouffet is a Professor of Paediatrics in the University of Toronto, Garron Family Chair in Childhood Cancer Research and Head of the Neuro-oncology Section in the Division of Haematology/Oncology at The Hospital for Sick Children, Toronto.

He graduated in 1980 from the medical school at the University of Lyon. Following graduation he trained and practiced in Lyon; he was Head of the Department of Neuro-oncology, Centre Leon Berard, during the period 1992-1995. Dr. Bouffet then moved to the United Kingdom where he was Consultant Paediatric Oncologist at the Hospital for Sick Children, Bristol (1996-1998) and the Royal Marsden Hospital, Sutton UK (1998-2000). In 2000 he was recruited to The Hospital for Sick Children in Toronto to develop and Head a multidisciplinary paediatric Neuro-oncology Program within the Division of Haematology/Oncology.

In 1998-2001 he was co-Chairman of the Brain Tumour Committee of the International Society of Pediatric Oncology (SIOP) and is currently Chair of the Canadian Paediatric Brain Tumour Consortium. Dr. Bouffet is a member of the steering committee of the brain tumour committee of the Children's Oncology Group, and chair of the Infant Brain Tumours Committee. He is a Senior Associate Scientist in the Research Institute at the Hospital for Sick Children.

Dr. Bouffet's research interests are in the area of novel treatments and clinical trials in children with brain tumours. He is the author or co-author of over 260 peer-reviewed manuscripts and author/co-author on numerous book chapters in the field of neuro-oncology. He was the recipient of several awards, including the Alvin Zipursky Teaching Award, the Claus Wirsig Humanitarian Award, the Richard Rowe Award for Clinical Excellence in Paediatric Medical Care. In 2011, he became the inaugural recipient of the Garron Family Chair in Childhood Cancer Research.

Dr. Maryam Fouladi

Medical Director, Neuro-Oncology Program. Cincinnati Children's Principal Investigator, Collaborative Ependymoma Research Network

Maryam Fouladi, MD, MSc, graduated from the University of Toronto School of Medicine, and completed her pediatric residency and hematology/oncology fellowship training at the Hospital for Sick Children in Toronto, Canada.

Dr. Fouladi then completed her neuro-oncology fellowship training at St Jude Children's Research Hospital, and later completed further training in the molecular pharmacology department at St Jude before becoming a neuro-oncology faculty member in 2000. She served as the Chair of the Phase I Committee at St Jude.

Dr. Fouladi moved to Cincinnati Children's in 2008 to direct the neuro-oncology program. She is currently chair for the CNS Tumor New Agent Committee for the Children's Oncology Group. She is a member of the Steering Committee for the COG CNS Tumor Committee as well as the Developmental Theerapeutics group at COG, and is a member of the Collaborative Ependymoma Research Network (CERN).

She serves as local and national study chair through CERN, COG and the Pediatric Brain Tumor Consortium, for clinical trials that test new approaches to treat children with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.

Dr. Darren Hargrave

Consultant Paediatric Oncologist at Great Ormond Street Hospital in London

Dr. Hargrave is a Consultant Paediatric Oncologist at Great Ormond Street Hospital (GOSH) for Children in London, UK. His clinical speciality is neuro-onology and he leads the Experimental Cancer Therapeutics programme at GOSH.

Dr. Hargrave trained in the UK and Canada and has worked at the Hospital for Sick Children in Toronto, the Royal Marsden Hospital and now at GOSH. His particular interest is malignant glioma, including brainstem tumours (Diffuse Intrinsic Pontine Glioma- DIPG) and he has led several completed, on-going and planned clinical trials in these poor prognosis brain tumours.

He currently Chairs the European Paediatric High Grade Glioma group. Dr. Hargrave is also involved with collaborative research investigating the molecular biology and advanced functional imaging of malignant glioma and DIPG. The Experimental Cancer Therapeutics programme aims to develop new therapies against high risk childhood cancer and includes targeted and immune directed therapy strategies working with academics and Pharmaceutical partners.

One of his career aims is to help deliver an improvement in the survival and quality of life with children with high risk brain tumours such as DIPG.

Prof. Charles Keller

Associate Professor and Leader of the Pediatric Cancer Biology Program in the Pape' Family Pediatric Research Institute, Department of Pediatrics, Oregon Health & Science University

Dr. Keller's research focuses on the development of more effective, less toxic therapies for the childhood brain tumor, medulloblastoma, and the childhood muscle cancer, rhabdomyosarcoma. His special interest is advanced disease that has spread beyond the initial location of the cancer.

Dr. Keller is an Associate Professor and Leader of the Pediatric Cancer Biology Program in the Pape' Family Pediatric Research Institute, Department of Pediatrics, Oregon Health & Science University. Dr. Keller also directs the Pediatric Preclinical Testing Initiative, an NCI-affiliated childhood cancer drug testing program. He co-chairs the brain tumor developmental therapeutics committee (CNS-DVL) of the Children's Oncology Group and is a member of the soft tissue sarcoma (STS) committee of COG.

Dr. Keller previously attended Tulane University where he received a degree in Biomedical Engineering prior to attending Baylor College of Medicine where he received his M.D. degree. After completing his internship and residency in Pediatrics at Texas Children's Hospital, Dr. Keller trained in Pediatric Hematology-Oncology at the University of Utah and with 2007 Nobel laureate, Mario Capecchi.

More information can be seen on his blog, www.kellerlabblog.blogspot.com

Dr. Clinton Stewart

Full Member in the Department of Parmaceutical Sciences at St. Jude Children's Research Hospital

Dr. Clinton Stewart is a Full Member in the Department of Pharmaceutical Sciences at St. Jude Children's Research Hospital and Professor of Pediatrics and Clinical Pharmacy at the University of Tennessee, Memphis. He received his B.S. degree in Pharmacy from Auburn University and his Doctor of Pharmacy from the University of Tennessee, Memphis. After completing a postdoctoral fellowship at St. Jude under the mentorship of Dr. William E. Evans, Dr. Stewart joined the University of Tennessee College of Pharmacy faculty; in 1991, he joined the St. Jude faculty.

Dr. Stewart is an active member of several professional organizations, including the American Association of Pharmaceutical Scientists, the American Society of Clinical Oncology, and the American Association of Cancer Research. His research efforts are focused in the area of pediatric clinical pharmacology, addressing clinically relevant problems of cancer therapeutics in children. Current research efforts include the use of preclinical models to enhance design of clinical trials of new agents in children with cancer and the use of pharmacokinetics as a method to optimize drug exposure in children with cancer.

Dr. Stewart has authored or co-authored more than 200 peer-reviewed articles and book chapters. Co-chair of the Pharmacology Committee of the NIH-funded Pediatric Brain Tumor Consortium, Dr. Stewart has an active research program focused on developing a better understanding of the CNS penetration of anticancer drugs.

Sign up for updates

To unsubscribe click here